Zymeworks Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In Endometrial Cancer Eisai Co.

Zymeworks Inc (NYSE: ZYME ) said that in conjunction with the renewed focus on key priorities and cost-efficiency, ten members (or 50%) of the former senior management team would be leaving the Company. Additionally, in line with these reductions in the senior management team, a Company-wide decrease in the workforce will be initiated with a target of reducing Full story available on Benzinga.com

Zymeworks (ZYME) confirms 2022 and 2023 clinical development milestones for zanidatamab and ZW49.In addition, ten members (or 50%) of the former senior management team (including the

RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks are highlighted in this Screen of the Week article.

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Zymeworks Inc (ZYME) shares closed today at 1.5% above its 52 week low of $14.88, giving the company a market cap of $702M. The stock is currently down 7.9% year-to-date, down 70.3% over the past 12 months, and up 16.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 59.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 895.9% The company's stock price performance over the past 12 months lags the peer average by 130.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Zymeworks shares are down today after naming former board member Kenneth Galbraith as CEO and chair after the closing bell yesterday.

Ali Tehrani will leave the positions of CEO and president by Feb. 1, and biotech industry veteran Kenneth Galbraith will become chair and CEO

Equities research analysts predict that Zymeworks Inc. (NYSE:ZYME) will report $11.19 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Zymeworks earnings. The lowest sales estimate is $2.50 million and the highest is $22.00 million. Zymeworks reported sales of $15.68 million in the same quarter []

Brokerages expect that Zymeworks Inc. (NYSE:ZYME) will report earnings per share (EPS) of ($1.07) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Zymeworks earnings, with the lowest EPS estimate coming in at ($1.25) and the highest estimate coming in at ($0.92). Zymeworks reported earnings per share of ($0.74) []

During the last session, Zymeworks Inc. (NYSE:ZYME)s traded shares were 0.52 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stocks price was $16.33, reflecting an intraday gain of 5.49% or $0.85. The 52-week high for the ZYME share is $59.03, that puts it down -261.48 Could Zymeworks Inc. (NYSE: ZYME) Regain All Of Its Losses Given A -21.85% Dip From High? Read More »

The moving averages on the daily timeframe suggest a bearishness in price, as the 20, 50, 100 and 200 are all in a bearish alignment -- meaning the shorter duration moving averages are below the longer duration averages, implying a stable downward trend. The post Zymeworks Inc (ZYME): Price Now Near $14.96; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .

Shares of Zymeworks Inc. (NYSE:ZYME) hit a new 52-week low during trading on Monday . The company traded as low as $15.65 and last traded at $15.84, with a volume of 27711 shares traded. The stock had previously closed at $16.07. A number of research analysts have recently commented on the company. Raymond James lowered []